MentionFox
Home › funding signals › Tempest Therapeutics, Inc.
Form D · on the record

Tempest Therapeutics — $2M Form D filing, April 2026

Tempest Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-04-03.

Tempest Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on April 3, 2026. Tempest Therapeutics, Inc. trades on Nasdaq as TPST; it was formerly Millendo Therapeutics, Inc. The filing reports $2M sold. Its industry group is Biotechnology. It names Matthew Angel (Executive Officer, Director), Nicholas Maestas (Executive Officer), Michael Raab (Director) (SEC Form D, April 3, 2026).

In its own words: “Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.” (tempesttx.com, checked November 1, 2026)

Sell to companies like Tempest Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

88 companies raised this week, 1 had other signals.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

fal - Features & Labels, Inc.$1BAI and software
fal - Features & Labels, Inc.$350MAI and software
SIERRA INTERNATIONAL NETWORK INC$300MAI and software
Zai Lab Ltd$250MBiotech
Databento Inc.$100MAI and software
Check one company free All companies that raised this week

5 more Biotechnology raises in California, April 2026 ↓

Is this your company?

Key facts

Run the free check on Tempest Therapeutics, Inc. →

Tempest Therapeutics, Inc.

New Form D on file · 2026-04-03 · the record

$2M
raise on the record
D
filing
3
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-04-03
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedBRISBANE, CALIFORNIA
CIK1544227
Accession0001231919-26-000307

Pitching, partnering or investing alongside them? See who really runs and owns Tempest Therapeutics, Inc.

Free to see. No signup.

Keep reading

More on the people and the money behind Tempest Therapeutics, Inc., from the filings we hold.

More raises like this

Biotechnology raises by companies based in California, filed in April 2026, largest first.

What do you want to do with Tempest Therapeutics, Inc.?

Get the full cited report on Tempest Therapeutics, Inc.

What the filing shows about Tempest Therapeutics, Inc.

  • 3 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look Tempest Therapeutics, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Tempest Therapeutics, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives Tempest Therapeutics, Inc.'s address as 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005.

What the filing says

  • Offered: $1,999,539. Sold: $1,999,539. Left to sell: nothing, all of it is sold. (filing)
  • Investors: 3 had already invested. (filing)
  • Date of first sale: March 20, 2026. (filing)
  • Types of securities: Equity; Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Tempest Therapeutics, Inc. See pricing

Is Tempest Therapeutics, Inc. a real, registered company?

Tempest Therapeutics, Inc. is a registered filer with the SEC (CIK 1544227) and has filed since 2026-04-03. 3 filings are on record, the latest on 2026-10-14.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Tempest Therapeutics, Inc.?

Tempest Therapeutics, Inc.'s Form D of 2026-04-03 names Matthew Angel, Nicholas Maestas, Michael Raab and 3 more as its officers, directors or promoters.

How much has Tempest Therapeutics, Inc. raised?

Its new offerings report $13.56M sold across 3 offerings, as its own filings state.

Filing history · 3 filings on this registrant
Form D · 2026-04-03 · $2M · this pageForm D · 2026-06-23 · $4.06MForm D · 2026-10-14 · $7.50M 2026-04-03 2026-10-14

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $2M, filed week of Mar 30

Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $2M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Tempest Therapeutics, Inc.?

What the filing shows about Tempest Therapeutics, Inc.

  • 3 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Tempest Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Tempest Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Tempest Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

More on Tempest Therapeutics, Inc.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Tempest Therapeutics, Inc.: Raised $2M, Form D filed 2026-04-03
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/tempest-therapeutics-inc-form-d-26000001
Last updated 2026-10-20
Primary record: SEC filing 1 · SEC filing 2
Tempest Therapeutics raised $2M — SEC Form D filing, April 2026. MentionFox, 2026-10-20. https://mentionfox.com/funding/tempest-therapeutics-inc-form-d-26000001